These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 8744803)
1. Relationship between c-erbB-2 oncoprotein, epidermal growth factor receptor, and estrogen receptor expression in patients with ductal breast carcinoma. Association with tumor phenotypes. Harłoziñska A; Bar JK; Wenderski R; Bebenek M In Vivo; 1996; 10(2):217-22. PubMed ID: 8744803 [TBL] [Abstract][Full Text] [Related]
2. Prospective studies of p53 and c-erbB-2 expression in relation to clinicopathological parameters of human ductal breast cancer in the second stage of clinical advancement. Bebenek M; Bar JK; Harlozinska A; Sedlaczek P Anticancer Res; 1998; 18(1B):619-23. PubMed ID: 9568187 [TBL] [Abstract][Full Text] [Related]
3. C-erbB-2 oncoprotein amplification in infiltrating ductal carcinoma of breast relates to high histological grade and loss of oestrogen receptor protein. Looi LM; Cheah PL Malays J Pathol; 1998 Jun; 20(1):19-23. PubMed ID: 10879259 [TBL] [Abstract][Full Text] [Related]
4. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Tolgay Ocal I; Dolled-Filhart M; D'Aquila TG; Camp RL; Rimm DL Cancer; 2003 Apr; 97(8):1841-8. PubMed ID: 12673709 [TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. McCann AH; Dervan PA; O'Regan M; Codd MB; Gullick WJ; Tobin BM; Carney DN Cancer Res; 1991 Jun; 51(12):3296-303. PubMed ID: 1674898 [TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer. Ioachim E; Kamina S; Athanassiadou S; Agnantis NJ Anticancer Res; 1996; 16(5B):3141-7. PubMed ID: 8920782 [TBL] [Abstract][Full Text] [Related]
7. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast. Hussein MR; Abd-Elwahed SR; Abdulwahed AR Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077 [TBL] [Abstract][Full Text] [Related]
8. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579 [TBL] [Abstract][Full Text] [Related]
9. The significance of c-erbB-2 overexpression and p53 expression in patients with axillary lymph node--negative breast cancer: a tissue microarray study. Ko SS; Na YS; Yoon CS; Park JY; Kim HS; Hur MH; Lee HK; Chun YK; Kang SS; Park BW; Lee JH Int J Surg Pathol; 2007 Apr; 15(2):98-109. PubMed ID: 17478762 [TBL] [Abstract][Full Text] [Related]
10. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma. González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346 [TBL] [Abstract][Full Text] [Related]
11. Distribution of prognostically unfavourable product of c-erbB-2 oncogene and EGF-R in carcinomas of the breast and uterine cervix. Ray A; Naik SL; Sharma BK Indian J Physiol Pharmacol; 2002 Oct; 46(4):423-33. PubMed ID: 12683217 [TBL] [Abstract][Full Text] [Related]
12. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Steinman S; Wang J; Bourne P; Yang Q; Tang P Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367 [TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical co-expression of c-erbb-2/Neu oncoprotein, altered tumour suppressor (p53) protein, EGF-R and EMA in histological subtypes of infiltrating duct carcinoma of the breast. Sharma BK; Ray A; Kaur S; Gupta S Indian J Exp Biol; 1999 Mar; 37(3):223-7. PubMed ID: 10641149 [TBL] [Abstract][Full Text] [Related]
14. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis. D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704 [TBL] [Abstract][Full Text] [Related]
15. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan. Sharif MA; Mamoon N; Mushtaq S; Khadim MT J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313 [TBL] [Abstract][Full Text] [Related]
16. Correlated expression of erbB-3 with hormone receptor expression and favorable clinical outcome in invasive ductal carcinomas of the breast. Lee Y; Cho S; Seo JH; Shin BK; Kim HK; Kim I; Kim A Am J Clin Pathol; 2007 Dec; 128(6):1041-9. PubMed ID: 18024331 [TBL] [Abstract][Full Text] [Related]
17. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast. Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078 [TBL] [Abstract][Full Text] [Related]
18. Correlation of KIT and EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation. Tsuda H; Morita D; Kimura M; Shinto E; Ohtsuka Y; Matsubara O; Inazawa J; Tamaki K; Mochizuki H; Tamai S; Hiraide H Cancer Sci; 2005 Jan; 96(1):48-53. PubMed ID: 15649255 [TBL] [Abstract][Full Text] [Related]
19. The expression of products of oncogens c-erbB2 and EGFR and proliferating antigens Ki67 and PCNA in primary invasive ductal cancer of female breast. Jeziorski A; Blonski JZ; Niewiadomska H J Exp Clin Cancer Res; 2000 Mar; 19(1):61-7. PubMed ID: 10840938 [TBL] [Abstract][Full Text] [Related]
20. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Viale G; Rotmensz N; Maisonneuve P; Bottiglieri L; Montagna E; Luini A; Veronesi P; Intra M; Torrisi R; Cardillo A; Campagnoli E; Goldhirsch A; Colleoni M Breast Cancer Res Treat; 2009 Jul; 116(2):317-28. PubMed ID: 18839307 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]